Sponsored · Whitepaper
Bribery and Corruption in the Life Sciences Sector
How susceptible is the life sciences sector to bribery and corruption? Through what channels—such as government contracts—are instances of bribery and corruption likely to emerge? What preventative steps can organizations take to deter bribery and corruption? Does the life sciences sector pose any particular challenges when drafting these policies and procedures?Download Now
Also available for download: Managing Third-Party Risks Across Your Life Sciences Business
Learn more in this whitepaper featuring a panel of experts representing GE Healthcare, Novartis, RSM, and others.